# entyvio achieves disease clearance in ulcerative colitis trial > entyvio treatment targets disease clearance in ulcerative colitis, reducing complications by 70%. - Title: entyvio achieves disease clearance in ulcerative colitis trial - Summary: entyvio treatment targets disease clearance in ulcerative colitis, reducing complications by 70%. entyvio vedolizumab prolongs time to ulcerative colitis… - Keywords: ulcerative colitis, entyvio, vedolizumab, disease clearance, symptomatic remission, takeda, phase 4 trial, uc complications, gut healing, inflammatory bowel disease, money, business - Source: Financialpost — https://financialpost.com/pmn/business-wire-news-releases-pmn/first-and-only-ulcerative-colitis-treat-to-target-trial-shows-treating-to-disease-clearance-vs-symptomatic-remission-with-entyvio-vedolizumab-prolongs-time-to-first-disease-related-complicati - Read time: 1 min - Topics: ulcerative colitis, entyvio, vedolizumab, disease clearance, symptomatic remission, takeda, phase 4 trial, uc complications, gut healing, inflammatory bowel disease, money, business ## verdict trial results verdict trial shows treating ulcerative colitis to disease clearance reduces complications by 70% compared to symptomatic remission. > verdict is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy ## disease clearance definition disease clearance combines corticosteroid-free symptomatic, endoscopic and histologic remission for deeper healing. > disease clearance is a treatment target that combines three levels of remission: corticosteroid-free symptomatic remission, endoscopic remission, and histologic remission ## trial design verdict randomized patients to three treatment targets: symptomatic remission, symptomatic plus endoscopic remission, or disease clearance. > verdict randomized adults with moderate to severe ulcerative colitis to three increasingly stringent csf treatment targets ## key findings 57% of patients achieved disease clearance by week 16, reducing uc complications by 70% over 80 weeks. > treating to stringent composite targets with entyvio reduced uc complication risk by ~70%, up to 80 weeks after target achievement ## gut healing evidence molecular analysis shows inflammation pathways improved in patients achieving disease clearance by week 16. > proteomic and transcriptomic analyses identified distinct molecular patterns among bio-naïve patients who achieved disease clearance by week 16 ## complication rates 51 uc-related complications occurred, with rescue therapy being the most frequent complication. > 51 uc-related complications occurred, with use of rescue therapy being the most frequent ## safety profile adverse events were similar across groups with no new safety signals identified. > the safety profile observed throughout 96 weeks was generally consistent with previously reported data, with no new safety signals identified ## takeda's perspective takeda emphasizes entyvio's ability to achieve gut healing without corticosteroids in bio-naïve patients. > for people living with uc, symptom relief does not always tell the full story of what is happening beneath the surface ## clinical significance disease clearance targets may reduce long-term uc complications and improve quality of life. > the impact of ulcerative colitis can extend well beyond day-to-day symptoms ## next steps further research needed to understand molecular changes in disease clearance and long-term outcomes. > these exploratory findings may contribute to a better understanding of the biology associated with disease clearance ## Key takeaway entyvio vedolizumab prolongs time to ulcerative colitis complications by 70% when achieving disease clearance versus symptomatic remission.